# A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD

> **NCT06558708** · PHASE2 · RECRUITING · sponsor: **Gan and Lee Pharmaceuticals, USA** · enrollment: 60 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** GZR101 Injection
- **DRUG:** GZR33 Injection
- **DRUG:** Insulin aspart

## Key facts

- **NCT ID:** NCT06558708
- **Lead sponsor:** Gan and Lee Pharmaceuticals, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-28
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06558708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06558708, "A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06558708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*